177 related articles for article (PubMed ID: 32374631)
21. Bayesian data integration and variable selection for pan-cancer survival prediction using protein expression data.
Maity AK; Bhattacharya A; Mallick BK; Baladandayuthapani V
Biometrics; 2020 Mar; 76(1):316-325. PubMed ID: 31393003
[TBL] [Abstract][Full Text] [Related]
22. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
Lei Z; Tan IB; Das K; Deng N; Zouridis H; Pattison S; Chua C; Feng Z; Guan YK; Ooi CH; Ivanova T; Zhang S; Lee M; Wu J; Ngo A; Manesh S; Tan E; Teh BT; So JB; Goh LK; Boussioutas A; Lim TK; Flotow H; Tan P; Rozen SG
Gastroenterology; 2013 Sep; 145(3):554-65. PubMed ID: 23684942
[TBL] [Abstract][Full Text] [Related]
23. Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas.
Li J; Akbani R; Zhao W; Lu Y; Weinstein JN; Mills GB; Liang H
Cancer Res; 2017 Nov; 77(21):e51-e54. PubMed ID: 29092939
[TBL] [Abstract][Full Text] [Related]
24. Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.
Liu C; Zhao J; Lu W; Dai Y; Hockings J; Zhou Y; Nussinov R; Eng C; Cheng F
PLoS Comput Biol; 2020 Feb; 16(2):e1007701. PubMed ID: 32101536
[TBL] [Abstract][Full Text] [Related]
25. Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.
Ali M; Khan SA; Wennerberg K; Aittokallio T
Bioinformatics; 2018 Apr; 34(8):1353-1362. PubMed ID: 29186355
[TBL] [Abstract][Full Text] [Related]
26. Impact of between-tissue differences on pan-cancer predictions of drug sensitivity.
Lloyd JP; Soellner MB; Merajver SD; Li JZ
PLoS Comput Biol; 2021 Feb; 17(2):e1008720. PubMed ID: 33630864
[TBL] [Abstract][Full Text] [Related]
27. Introduction: Cancer Gene Networks.
Clarke R
Methods Mol Biol; 2017; 1513():1-9. PubMed ID: 27807826
[TBL] [Abstract][Full Text] [Related]
28. A pan-cancer proteomic perspective on The Cancer Genome Atlas.
Akbani R; Ng PK; Werner HM; Shahmoradgoli M; Zhang F; Ju Z; Liu W; Yang JY; Yoshihara K; Li J; Ling S; Seviour EG; Ram PT; Minna JD; Diao L; Tong P; Heymach JV; Hill SM; Dondelinger F; Städler N; Byers LA; Meric-Bernstam F; Weinstein JN; Broom BM; Verhaak RG; Liang H; Mukherjee S; Lu Y; Mills GB
Nat Commun; 2014 May; 5():3887. PubMed ID: 24871328
[TBL] [Abstract][Full Text] [Related]
29. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
[TBL] [Abstract][Full Text] [Related]
30. From drug response profiling to target addiction scoring in cancer cell models.
Yadav B; Gopalacharyulu P; Pemovska T; Khan SA; Szwajda A; Tang J; Wennerberg K; Aittokallio T
Dis Model Mech; 2015 Oct; 8(10):1255-64. PubMed ID: 26438695
[TBL] [Abstract][Full Text] [Related]
31. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
32. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
33. Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
Stühler E; Braune S; Lionetto F; Heer Y; Jules E; Westermann C; Bergmann A; van Hövell P;
BMC Med Res Methodol; 2020 Feb; 20(1):24. PubMed ID: 32028898
[TBL] [Abstract][Full Text] [Related]
34. Quantitative phosphoproteomics reveals molecular pathway network alterations in human early-stage primary hepatic carcinomas: potential for 3P medical approach.
Zhang Y; Li N; Yang L; Jia W; Li Z; Shao Q; Zhan X
EPMA J; 2023 Sep; 14(3):477-502. PubMed ID: 37605650
[TBL] [Abstract][Full Text] [Related]
35. Modeling gene-wise dependencies improves the identification of drug response biomarkers in cancer studies.
Nikolova O; Moser R; Kemp C; Gönen M; Margolin AA
Bioinformatics; 2017 May; 33(9):1362-1369. PubMed ID: 28082455
[TBL] [Abstract][Full Text] [Related]
36. Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers.
Cohen AL; Piccolo SR; Cheng L; Soldi R; Han B; Johnson WE; Bild AH
BMC Med Genomics; 2013 Sep; 6():35. PubMed ID: 24079712
[TBL] [Abstract][Full Text] [Related]
37. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.
Wu Z; Doondeea JB; Gholami AM; Janning MC; Lemeer S; Kramer K; Eccles SA; Gollin SM; Grenman R; Walch A; Feller SM; Kuster B
Mol Cell Proteomics; 2011 Dec; 10(12):M111.011635. PubMed ID: 21955398
[TBL] [Abstract][Full Text] [Related]
38. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract][Full Text] [Related]
39. Survey and comparative assessments of computational multi-omics integrative methods with multiple regulatory networks identifying distinct tumor compositions across pan-cancer data sets.
Wei Z; Zhang Y; Weng W; Chen J; Cai H
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32533167
[TBL] [Abstract][Full Text] [Related]
40. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
Carroll MJ; Parent CR; Page D; Kreeger PK
BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
